Business Description
MiNK Therapeutics Inc
NAICS : 541714
SIC : 2833
ISIN : US6036932019
Total Employee Number:
15Description
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.84 | |||||
Equity-to-Asset | -1.22 | |||||
Debt-to-Equity | -0.41 | |||||
Debt-to-EBITDA | -0.41 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 32 | |||||
3-Year EPS without NRI Growth Rate | 29.6 | |||||
3-Year FCF Growth Rate | 37.5 | |||||
3-Year Book Growth Rate | -194.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -12.16 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 21.53 | |||||
9-Day RSI | 32.41 | |||||
14-Day RSI | 39.16 | |||||
3-1 Month Momentum % | 2.33 | |||||
6-1 Month Momentum % | -5.91 | |||||
12-1 Month Momentum % | 69.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.38 | |||||
Quick Ratio | 1.38 | |||||
Cash Ratio | 1.31 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -11.6 | |||||
Shareholder Yield % | -6.48 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROA % | -134.58 | |||||
ROIC % | -173.98 | |||||
3-Year ROIIC % | 390.32 | |||||
ROC (Joel Greenblatt) % | -2747.65 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -3.48 | |||||
EV-to-Forward-EBIT | -4.01 | |||||
EV-to-EBITDA | -3.53 | |||||
EV-to-FCF | -7.08 | |||||
Earnings Yield (Greenblatt) % | -28.74 | |||||
FCF Yield % | -11.94 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:INKT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
MiNK Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.82 | ||
| Beta | 1.3835 | ||
| 3-Year Sharpe Ratio | -0.07 | ||
| 3-Year Sortino Ratio | -0.15 | ||
| Volatility % | 112.2 | ||
| 14-Day RSI | 39.16 | ||
| 14-Day ATR ($) | 0.75702 | ||
| 20-Day SMA ($) | 11.8475 | ||
| 12-1 Month Momentum % | 69.33 | ||
| 52-Week Range ($) | 7.2 - 76 | ||
| Shares Outstanding (Mil) | 4.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
MiNK Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
MiNK Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-13 08:30 | In 129 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 128 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-14 08:30 | In 38 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 37 days | ||
| General meeting for 2026 | 2026-06-17 09:30 | 11.81 (-5.37%) | ||
| First quarter earnings conference call for 2026 | 2026-05-15 08:30 | 10.51 (-5.66%) | ||
| First quarter earnings results for 2026 | 2026-05-15 | 10.51 (-5.66%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-31 08:30 | 10.52 (-8.44%) | ||
| Annual report for 2025 | 2026-03-31 | 10.52 (-8.44%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-31 | 10.52 (-8.44%) |
Show
Entries
MiNK Therapeutics Inc Frequently Asked Questions
What is MiNK Therapeutics Inc(INKT)'s stock price today?
The current price of INKT is $10.62. The 52 week high of INKT is $76.00 and 52 week low is $7.20.
When is next earnings date of MiNK Therapeutics Inc(INKT)?
The next earnings date of MiNK Therapeutics Inc(INKT) is 2026-08-14 Est..
Does MiNK Therapeutics Inc(INKT) pay dividends? If so, how much?
MiNK Therapeutics Inc(INKT) does not pay dividend.
Guru Commentaries on NAS:INKT
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on MiNK Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers